natureresearch

Corresponding author(s): Stefan Pfeffer and Irmgard Sinning

Last updated by author(s): Jan 15, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and the Editorial Policy Checklist.

- .			
St	at	ıst	ICS

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
x		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
×		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x		A description of all covariates tested
x		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
×		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
×		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
50.	F+\A	vare and code

Software and code

Policy information about availability of computer code

Data collection

Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR state that no software was used.

Data analysis

Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The following cryo-EM densities for the Ebp1-ribosome complex have been deposited in the EMDataBank: Ebp1-60S segment at full-spatial resolution from 2-body multibody refinement (EMD-10610); Ebp1-ES27L segment from 3-body multibody refinement (EMD-10609); Ebp1-60S segment from 2-body multibody refinement after sorting for ES27L conformation (EMD-10608). The atomic coordinates for Ebp1 and interacting ribosomal components have been deposited in the RCSB with accession ID 6SXO. For visualization of the model in context of the entire human 80S ribosome, we recommend to superpose our atomic coordinates to the structure of the human ribosome solved at 2.9 Å resolution (PDB-ID 6EKO), which is virtually identical except for the Ebp1-interacting region. Other data are available from the corresponding authors upon reasonable request.

Field-spe	ecitic re	porting		
Please select the or	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
🗶 Life sciences	□В	ehavioural & social sciences		
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces stu	udy design		
All studies must dis	close on these	points even when the disclosure is negative.		
Sample size	n/a			
Data exclusions	n/a			
Replication	n/a			
Randomization	n/a			
Blinding	n/a			
We require informatic system or method list Materials & ext n/a Involved in th	on from authors a ted is relevant to perimental so the study cell lines ogy and other organism tearch participant	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging		
Antibodies				
Antibodies used		ıman anti-Ebp1: ABE43, Lot # 2445967, Merck Millipore; anti-rabbit IgG antibody: 111-035-144, Jackson ImmunoResearch.		
Validation		tp://www.merckmillipore.com/DE/de/product/msds/MM_NF-ABE43?Origin=PDP		
Eukaryotic c	ell lines			
Policy information about <u>cell lines</u>				
Cell line source(s)	HeLa-S3 cells		
Authentication		None of the cell lines were authenticated		
Mycoplasma con	tamination	All cell lines have been tested negative.		

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Commonly misidentified lines (See <u>ICLAC</u> register)